Object Pharma

What Object Pharma does

Object Pharma is a privately held, preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Aliso Viejo, California. The company is developing OP01, a proprietary botulinum neurotoxin (BoNT) formulation designed exclusively for mental health therapeutics, with its first indication being Major Depressive Disorder (MDD). The platform targets the substantial unmet need in treatment-resistant depression, where approximately 50% of patients do not recover after two antidepressant medication trials and roughly 65% of treated patients require more effective alternatives. The BoNT class has demonstrated clinical evidence of efficacy and safety in MDD trials, and OP01 is positioned as clinically unique compared to currently marketed products in the same molecular class (such as onabotulinumtoxinA).

The company operates a dual structure. The lead program, OP01, is in preclinical development for MDD with planned expansion into pediatric and elderly mental health populations. To finance development without external venture capital, Object Pharma runs Metabiologics, a revenue-generating sub-brand that sells critical reagents to the broader botulinum neurotoxin research community. This structure allows the company to self-fund preclinical activities while building proprietary manufacturing expertise in BoNT production. Go-to-market for OP01 is not yet defined given its preclinical status, though the company anticipates standard pharmaceutical distribution channels (hospitals, psychiatric clinics, specialty pharmacies) following regulatory approval.

Object Pharma is led by CEO Kenton Abel, PhD, President Dan Radecki, MA, PhD, and CSO Aaron Chamberlian, PhD, with scientific advisory support from leading clinical psychiatrists and neuromodulator researchers affiliated with the University of Pennsylvania Perelman School of Medicine, UT Dell Medical School, and prominent private aesthetic medicine practices. In April 2026, the company announced its first international partnership with Poland's TZF Polfa to combine research and manufacturing capabilities for MDD neuromodulator therapeutics, signaling an intent to access European manufacturing and regulatory pathways.

Name

Object Pharma

Legal name

Object Pharma

Website

https://objectpharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Object Pharma is a preclinical-stage biopharmaceutical company developing OP01, a proprietary botulinum neurotoxin exclusively for mental health disorders, with first indication being Major Depressive Disorder. The company self-funds development through its Metabiologics reagent division.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Neuropsychiatric Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIACAC

Neurology & CNS Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAIALAD

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

• Botulinum neurotoxin therapeutics
• Mental health biopharmaceuticals
• Major depressive disorder treatment
• Neurotoxin reagent supply
• Preclinical neuropsychiatric drug development

Headquarters

HQ city

Aliso Viejo

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

Core offering

Object Pharma is a biopharmaceutical company developing OP01, a proprietary botulinum neurotoxin therapeutic candidate for the treatment of mental health disorders, with Major Depressive Disorder (MDD) as the lead indication. The company self-funds its preclinical development through Metabiologics, a revenue-generating sub-division that supplies critical reagents to the botulinum neurotoxin research community.

Product overview

Object Pharma is an innovative fully integrated biopharma company with two distinct offerings: OP01 is its core product candidate, a unique botulinum neurotoxin being developed exclusively for mental health disorders with Major Depressive Disorder as the first indication, and Metabiologics is a revenue-generating sub-brand that sells critical reagents to the botulinum neurotoxin community. These two divisions work together, with Metabiologics revenue supporting the preclinical development of OP01.

Differentiator

Problem solved

Functional benefit

Brands

• Metabiologics: A revenue-generating division of Object Pharma that sells critical reagents to the botulinum neurotoxin community.

Products and services

• OP01
• Metabiologics Reagents

Quantifiable outcome

• Over 280 million people worldwide affected by depression; Nearly 40% of patients do not receive adequate relief with oral medications; Up to 50% of individuals with MDD do not recover after two antidepressant medication trials; Approximately 65% of treated patients require better alternatives; $327B estimated US economic costs due to major depressive disorder

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves5 records

Expansion highlights4 records

Emerging players

• Compass Pathways: Clinical-stage company developing psilocybin therapy for treatment-resistant depression. Emerging player pursuing a novel psychiatric mechanism for the same TRD population Object Pharma targets.

Broad incumbents

• Supernus Pharmaceuticals: Specialty CNS pharmaceutical company with multiple neurology/CNS products. Broad incumbent comparable as a mid-sized specialty pharma operating in adjacent CNS therapeutic categories.
• AbbVie (Allergan Aesthetics): Markets Botox (onabotulinumtoxinA), the dominant botulinum neurotoxin product and the comparator molecule for OP01. AbbVie is the broad incumbent in BoNT therapeutics and aesthetics, providing both the competitive benchmark and the ultimate acquirer archetype for Object Pharma.
• Johnson & Johnson (Janssen): Markets Spravato (esketamine) for treatment-resistant depression. Broad incumbent in the TRD space where Object Pharma's OP01 will compete, with established commercial and reimbursement infrastructure.
• Ipsen: Markets Dysport (abobotulinumtoxinA), a major competing botulinum neurotoxin with both aesthetic and therapeutic indications. Broad incumbent in the same BoNT class as Object Pharma's OP01.

Direct peers

• Sage Therapeutics: Develops CNS specialty therapeutics including Zurzuvae (zuranolone) for postpartum depression and MDD. Direct peer in CNS specialty pharma targeting depression with novel mechanisms.
• Revance Therapeutics: Develops DaxibotulinumtoxinA, a next-generation botulinum neurotoxin approved for aesthetics and in development for therapeutics. Direct peer in novel BoNT R&D with comparable biologic manufacturing complexity and pipeline strategy.
• Axsome Therapeutics: Markets Auvelity, an NMDA-receptor-targeting antidepressant approved for MDD. Direct peer in CNS specialty pharma developing novel-mechanism depression therapeutics for treatment-resistant populations.
• Evolus: Markets Jeuveau (prabotulinumtoxinA), a newer aesthetic-focused botulinum neurotoxin. Comparable as a commercial-stage BoNT company pursuing novel neurotoxin variants in adjacent indications.

Regional players

• Hugel: Korean botulinum toxin manufacturer with global aesthetic and therapeutic ambitions (Bont botulinum toxin). Regional player in the BoNT space, comparable on manufacturing platform and molecule class.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Object Pharma